We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+41.42%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$70.6M
Cap. Flow
-$185M
Cap. Flow %
-13.36%
Top 10 Hldgs %
97.14%
Holding
14
New
1
Increased
2
Reduced
3
Closed
2

Top Buys

1
DMRA
Damora Therapeutics
DMRA
+$224M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$23.2M
3
ZBIO
Zenas BioPharma
ZBIO
+$3.37M

Top Sells

1
COGT icon
Cogent Biosciences
COGT
+$129M
2
APGE icon
Apogee Therapeutics
APGE
+$127M
3
NUVL icon
Nuvalent
NUVL
+$73.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.4M
5
ELVN icon
Enliven Therapeutics
ELVN
+$51.4M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMRA
1
Damora Therapeutics
DMRA
$1.94B
$226M 16.3%
+8,713,000
New +$224M
DNTH icon
2
Dianthus Therapeutics
DNTH
$5.77B
$213M 15.38%
2,537,191
+400,000
+19% +$23.2M
COGT icon
3
Cogent Biosciences
COGT
$6.68B
$212M 15.3%
5,503,418
-3,500,000
-39% -$129M
SYRE icon
4
Spyre Therapeutics
SYRE
$8.7B
$203M 14.64%
4,018,101
– –
ORKA
5
Oruka Therapeutics
ORKA
$5.59B
$182M 13.13%
3,705,262
– –
VRDN icon
6
Viridian Therapeutics
VRDN
$1.99B
$76.6M 5.53%
3,914,458
– –
ELVN icon
7
Enliven Therapeutics
ELVN
$3.8B
$72.7M 5.25%
1,855,644
-1,855,800
-50% -$51.4M
JBIO
8
Jade Biosciences
JBIO
$1.27B
$64M 4.62%
4,553,494
– –
CBIO
9
Crescent Biopharma
CBIO
$407M
$50.5M 3.65%
2,747,866
– –
ZBIO
10
Zenas BioPharma
ZBIO
$1.86B
$46.1M 3.33%
2,359,025
+150,000
+7% +$3.37M
APGE icon
11
Apogee Therapeutics
APGE
$10.1B
$25.1M 1.82%
298,647
-1,750,000
-85% -$127M
IKT icon
12
Inhibikase Therapeutics
IKT
$331M
$14.5M 1.05%
8,625,000
– –
KNSA icon
13
Kiniksa Pharmaceuticals
KNSA
$4.92B
– –
-1,319,688
Closed -$54.4M
NUVL icon
14
Nuvalent
NUVL
– –
-727,563
Closed -$73.2M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q1 2026 Portfolio in Review

As of Q1 2026, Fairmount Funds Management held 14 positions worth $1.38B, up 5.4% from $1.31B the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Fairmount Funds Management withdrew a net $185M in Q1 2026, closing 2 positions and reducing 3 holdings. Its most notable exit was Nuvalent, an estimated $73.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Fairmount Funds Management opened a new position in Damora Therapeutics worth $226M.

  • Fairmount Funds Management's largest Q1 2026 buy was Damora Therapeutics: 8,713,000 shares worth $226M.
  • Fairmount Funds Management added most to Dianthus Therapeutics in Q1 2026, an estimated $23.2M increase.
  • Fairmount Funds Management's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $129M.
  • Fairmount Funds Management fully exited Nuvalent in Q1 2026, selling an estimated $73.2M.
  • Fairmount Funds Management's ten largest holdings make up 97% of its $1.38B portfolio in Q1 2026.
  • Fairmount Funds Management opened 1 new position and closed 2 in Q1 2026.
  • Fairmount Funds Management's portfolio value rose 5.4% quarter-over-quarter to $1.38B.

Based on Fairmount Funds Management's 13F filing for Q1 2026, filed 15 May 2026.